Long-term safety of aromatase inhibitors in the treatment of breast cancer

Following promising data for metastatic breast cancer in terms of efficacy and safety profile, third-generation aromatase inhibitors (AI), anastrozole, letrozole, and exemestane, underwent a full development in early setting. If recent results consistently show the superiority of these agents over tamoxifen, the therapeutic strategies of AIs in adjuvant setting are still debated. Beyond the choice of clinical strategy, the long duration of exposure to AI in adjuvant setting required a full determination of the long-term toxicity profile of these agents. While all three AIs have either favorable (decreased incidence of hot flashes, gynecologic and thromboembolic side-effects) or unfavorable (skeletal complications, arthralgia, musculoskeletal pain, sexual dysfunction) class adverse events, some variability between AIs has been reported in side-effects as well as gastrointestinal, urogenital, neurologic, and visual disturbances, confirming the lack of interchangeability between the three AIs. The overall therapeutic index of AIs appears today superior to that of tamoxifen with proven improved efficacy and better toxicity profile. This review will explore the results from the available adjuvant AIs trials with a particular emphasis on safety profiles, quality of life, and therapeutic index, helping to define the present role of AIs in the adjuvant management of postmenopausal patients with breast cancer.

• Publication year

  2008

• Venue

  Therapeutics and Clinical Risk Management

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/TCRM.S1566PMID 18728707PMCID 2503653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

  2007influential reference
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007influential reference
• Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

  2006cited by this paper
• Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.

  2006cited by this paper
• The ne w e ngl and j our na l of medicine

  2006influential reference
• Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

  2006cited by this paper
• Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.

  2006influential reference
• Cardiovascular Safety Profiles of Aromatase Inhibitors

  2006cited by this paper
• Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

  2005cited by this paper
• Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

  2005cited by this paper
• Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial

  2005influential reference
• Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

  2005cited by this paper
• Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.

  2005influential reference
• Bringing molecular prognosis and prediction to the clinic.

  2005cited by this paper
• Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

  2005influential reference
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Anastrozole therapy and lipid profile: an update

  2004influential reference
• Breast cancer with synchronous metastases: trends in survival during a 14-year period.

  2004cited by this paper
• First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group.

  2004influential reference
• Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

  2004influential reference
• Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

  2004influential reference
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  2003cited by this paper
• An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.

  2003cited by this paper
• Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.

  2003cited by this paper
• The time course of bone fractures observed in the ATAC (‘Arimidex', Tamoxifen, Alone or in Combination) Trial

  2003cited by this paper
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

  2003cited by this paper
• Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

  2003cited by this paper
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

  2002cited by this paper
• Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

  2002influential reference
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• Update on cardiovascular disease in post-menopausal women.

  2002cited by this paper
• Uterine sarcoma associated with tamoxifen use.

  2002cited by this paper
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

  2002cited by this paper
• Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.

  2001influential reference
• Histological and biological evolution of human premalignant breast disease.

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

  2001cited by this paper
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

  2001cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000influential reference
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000influential reference
• Thrombophilic State in Breast Cancer

  1999cited by this paper
• Venous thromboembolism and cancer: a two-way clinical association.

  1997cited by this paper
• Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy

  1997cited by this paper
• Venous thromboembolism and cancer: a two-way clinical association.

  1997cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Formestane

  1996cited by this paper
• Annual hazard rates of recurrence for breast cancer after primary therapy.

  1996cited by this paper
• Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

  1996cited by this paper
• Gynaecological monitoring during tamoxifen therapy.

  1995cited by this paper
• Aromatase inhibitors in the treatment of breast cancer.

  1994cited by this paper
• Gynaecological monitoring during tamoxifen therapy.

  1994cited by this paper
• Aromatase Inhibitors: Clinical Pharmacology and Therapeutic Implications in Breast Cancer

  1992cited by this paper
• Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.

  1992cited by this paper
• Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

  1980cited by this paper
• Hormonal therapy in cancer of the breast. XIX. Effect of oral administration of Δ1‐testololactone on clinical course and hormonal excretion

  1962cited by this paper
• [Hormone therapy in cancer of the breast].

  1951cited by this paper
• On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

  1896cited by this paper

• Effect of Environmental Factors on Bone Remodelling: A Narrative Review

  2025cites this paper
• Impact of Endocrine Therapy for Cancer on Periodontal Health: A Systematic Review

  2025cites this paper
• Mechanisms of action for FDA-approved drugs targeting breast cancer

  2025cites this paper
• Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study

  2025cites this paper
• New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies.

  2025cites this paper
• Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach

  2025cites this paper
• Simultaneous quantification of four hormone therapy drugs by LC-MS/MS: Clinical applications in breast cancer patients.

  2024cites this paper
• Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment

  2024cites this paper
• Targeted and cytotoxic inhibitors used in the treatment of breast cancer.

  2024cites this paper
• Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer

  2024cites this paper
• Unveiling promising bioactives for breast cancer: a novel approach for herbal-based drug discovery

  2024cites this paper
• Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

  2024cites this paper
• Aromatase inhibitors evoke periorbital allodynia in mice via calcitonin gene-related peptide and its receptors in Schwann cells

  2024cites this paper
• A Rare Presentation of Metastatic Breast Cancer Manifesting As Diffuse Nodular Skin Lesions

  2023cites this paper
• Aromatase inhibitors: the journey from the state of the art to clinical open questions

  2023cites this paper
• Cardiotoxicity of Agents Used in Patients With Breast Cancer.

  2023cites this paper
• Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial.

  2022cites this paper
• Human adrenocortical carcinoma cell line (NCI-H295R): An in vitro screening model for the assessment of endocrine disruptors' actions on steroidogenesis with an emphasis on cell ultrastructural features.

  2022cites this paper
• Design, synthesis, molecular docking and molecular dynamics studies of novel triazolothiadiazine derivatives containing furan or thiophene rings as anticancer agents.

  2022cites this paper
• Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch

  2022cites this paper
• Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use

  2021influential citation
• Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis

  2021cites this paper
• Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.

  2021cites this paper
• Mechanisms of Endocrine Therapy Resistance in Breast Cancer.

  2021cites this paper
• Anticancer drugs in the aquatic ecosystem: Environmental occurrence, ecotoxicological effect and risk assessment.

  2021cites this paper
• Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia

  2021cites this paper
• Age-related disparities in older women with breast cancer.

  2020cites this paper
• A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay

  2019cites this paper
• Synthesis, biological activities and molecular docking studies of some novel 2,4,5-trisubstituted-1,2,4-triazole-3-one derivatives as potent tyrosinase inhibitors

  2019cites this paper
• The 'dark side' of tamoxifen : understanding adverse cellular response to endocrine therapy in ER+ breast cancer

  2019cites this paper
• A Case of Anastrozole-Induced Erythrocytosis

  2018cites this paper
• Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges

  2018influential citation
• Acquired resistance to aromatase inhibitors: where we stand!

  2018cites this paper
• Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again

  2018cites this paper
• The effect of third-generation aromatase inhibitors on aromatase avtivity in visceral adipose tissue

  2018cites this paper
• Genetic analysis of steroid pathway enzymes associated with adverse musculoskeletal effects of aromatase inhibitors

  2017cites this paper
• Sex‐dependent effects of letrozole on anxiety in middle‐aged rats

  2017cites this paper
• The Garvan calculator and fragility fracture risk

  2017cites this paper
• Methods for detection of the misuse of “anti-oestrogens and aromatase inhibitors” in sport

  2017influential citation
• Interventions for the Treatment of Aromatase Inhibitor–Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis

  2017cites this paper
• Post-menopausal breast cancer: from estrogen to androgen receptor

  2017cites this paper
• PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation

  2016cites this paper
• Tamoxifen metabolites can target both aromatase and estrogen receptors

  2015cites this paper
• Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer

  2015cites this paper
• Fall prevention in high-risk patients.

  2014cites this paper
• Enrichment-Based DNA Methylation Analysis Using Next-Generation Sequencing: Sample Exclusion, Estimating Changes in Global Methylation, and the Contribution of Replicate Lanes

  2014cites this paper
• Aromatase inhibitors in the breast cancer clinic: focus on exemestane.

  2014cites this paper
• Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey

  2014cites this paper
• Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1

  2014cites this paper
• Management Options for Hot Flashes in Cancer Patients

  2013cites this paper
• Acute Cerebrovascular Accident after Cisplatin Treatment in a Patient Taking Letrozole

  2013cites this paper
• Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane

  2013cites this paper
• [Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies].

  2012cites this paper
• Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.

  2012cites this paper
• Quality of life and psychological reactions in women on first line chemotherapy for metastatic breast cancer - Correlations to tumour response and predictive factors.

  2011cites this paper
• 22 – Nonestrogenic management of hot flashes

  2011cites this paper
• Nonestrogenic management of hot flashes.

  2011cites this paper
• Potential utility of natural products as regulators of breast cancer-associated aromatase promoters

  2011cites this paper
• Digital Ischemia in Patients with Solid Tumors: A Case Report and Review of the Literature

  2011cites this paper
• Musculoskeletal manifestations in patients with malignant disease

  2010cites this paper
• Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings

  2010cites this paper
• Estrogen Inhibits Glucocorticoid Action via Protein Phosphatase 5 (PP5)-mediated Glucocorticoid Receptor Dephosphorylation*

  2009cites this paper
• Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.

  2009cites this paper
• Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

  2009cites this paper
• International Journal of Women's Health Dovepress Clinical Utility of Exemestane in the Treatment of Breast Cancer

  year unknowncites this paper